FeesSafety
Pluang+

FDA grants accelerated approval to RYBREVANT FASPRO for advanced head and neck cancer treatment

Market News
06 Nov 2026, 04:03 WIB
PRNewsWire
View Source
Bullish
FDA grants accelerated approval to RYBREVANT FASPRO for advanced head and neck cancer treatment

Johnson & Johnson announced the FDA's accelerated approval of RYBREVANT FASPRO, a dual-targeted subcutaneous therapy for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum-based chemotherapy and anti-PD-(L)1 antibody treatment. This marks the first dual EGFR and MET targeted therapy approved for this cancer type, showing a 42% overall response rate in clinical trials. The approval offers a new treatment option for patients with limited alternatives and is contingent on ongoing confirmatory trials. The drug also has a known safety profile with manageable side effects.

Johnson & Johnson holds a substantial market cap of $665.19 billion as of November 6, 2026, 09:22 WIB, reflecting its major presence in the health sector. On Pluang, JNJ shares are priced at USD 270.00 with a dividend yield of 1.94%, though the stock experienced a 2.29% decline in the last day. The typical hold time of 130 days indicates steady investor interest despite recent selling pressure, with 63% of orders being sell and 37% buy at the same time.

More News (JNJ)

Three Dividend Kings offer $5,580 annual income from $250K investment despite lower yields than REITs or BDCs.

Three Dividend Kings offer $5,580 annual income from $250K investment despite lower yields than REITs or BDCs.

Investing $250,000 equally in three Dividend Kings—Johnson & Johnson, Coca-Cola, and Procter & Gamble—generates about $5,580 in annual passive income with a blended yield of 2.23%. These companies have raised dividends for over 60 years, offering rel...

Market News
Bullish
17 hours ago
Law firm investigates Johnson & Johnson over Q3 earnings and revenue miss amid talc litigation costs.

Law firm investigates Johnson & Johnson over Q3 earnings and revenue miss amid talc litigation costs.

Pomerantz LLP is investigating Johnson & Johnson for potential securities fraud following the company's Q3 2026 report showing net earnings of $210 million, heavily impacted by multi-billion dollar charges related to talc litigation settlements. The ...

Bearish
2 days ago
Three dividend stocks can generate $4,700 annually from a $100,000 portfolio for retirees.

Three dividend stocks can generate $4,700 annually from a $100,000 portfolio for retirees.

Retirees seeking steady income without selling shares can invest in three dividend stocks: Johnson & Johnson, Enterprise Products Partners, and Verizon. A $100,000 portfolio split evenly among these stocks yields about $4,700 annually, combining safe...

Market News
Bullish
3 days ago
4 blue-chip dividend stocks raised payouts through 2008 and 2020 crises, proving recession resilience.

4 blue-chip dividend stocks raised payouts through 2008 and 2020 crises, proving recession resilience.

Four blue-chip companies—Procter & Gamble, Johnson & Johnson, PepsiCo, and Walmart—consistently raised their dividends through the 2008 financial crisis and the 2020 pandemic. These firms operate in essential sectors like groceries, healthcare, and s...

Bullish
4 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App